Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2CHW

A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39

Summary for 2CHW
Entry DOI10.2210/pdb2chw/pdb
Related1E8Y 1E8Z 1HE8 2A4Z 2A5U 2CHX 2CHZ
DescriptorPHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT GAMMA ISOFORM, 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE (3 entities in total)
Functional Keywordstransferase/inhibitor, complex transferase-inhibitor, phosphoinositide, kinase, lipid, inhibitor, 3-kinase, signaling, quinazolinone, transferase, transferase-inhibitor complex
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains1
Total formula weight111207.07
Authors
Primary citationKnight, Z.A.,Gonzalez, B.,Feldman, M.E.,Zunder, E.R.,Goldenberg, D.D.,Williams, O.,Loewith, R.,Stokoe, D.,Balla, A.,Toth, B.,Balla, T.,Weiss, W.A.,Williams, R.L.,Shokat, K.M.
A Pharmacological Map of the Pi3-K Family Defines a Role for P110Alpha in Signaling
Cell(Cambridge,Mass.), 125:733-, 2006
Cited by
PubMed Abstract: Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined. We describe here an approach to pharmacologically interrogate the PI3-K family. A chemically diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochemically enumerated, revealing cryptic homologies across targets and chemotypes. Crystal structures of three inhibitors bound to p110gamma identify a conformationally mobile region that is uniquely exploited by selective compounds. This chemical array was then used to define the PI3-K isoforms required for insulin signaling. We find that p110alpha is the primary insulin-responsive PI3-K in cultured cells, whereas p110beta is dispensable but sets a phenotypic threshold for p110alpha activity. Compounds targeting p110alpha block the acute effects of insulin treatment in vivo, whereas a p110beta inhibitor has no effect. These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.
PubMed: 16647110
DOI: 10.1016/J.CELL.2006.03.035
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon